SMMT vs. WST: Summit Therapeutics vs. West Pharmaceutical Services Stock Comparison

Company Profile

Summit Therapeutics (SMMT) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but SMMT is classified in Biotechnology while WST is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. West Pharmaceutical Services (WST) has a non-negative beta of 1.13.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile West Pharmaceutical Services (WST) reports 21.23%, ranking against industry peers normally.

West Pharmaceutical Services (WST) at 18.81% converts revenue to bottom-line profit above its industry’s benchmark range, while Summit Therapeutics (SMMT) at 0.00% keeps roughly the typical share for its industry.

West Pharmaceutical Services (WST) at 25.37% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: West Pharmaceutical Services (WST) reports revenue growth of 6.25%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Only one side can be read here: West Pharmaceutical Services (WST) reports EPS growth of 1.49%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Summit Therapeutics (SMMT) at 5.99 and West Pharmaceutical Services (WST) at 2.82 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Summit Therapeutics (SMMT) at 0.04 and West Pharmaceutical Services (WST) at 0.11 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Summit Therapeutics (SMMT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a yield of 0.22%, ranking against industry peers normally.

Summit Therapeutics (SMMT) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a payout of 9.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: West Pharmaceutical Services (WST) trades at 44.87 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

A sales-based read is only available for West Pharmaceutical Services (WST), whose P/S ratio of 8.20 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

Both look rich against book: West Pharmaceutical Services (WST) at 9.40 sits in the upper P/B ratio quartile, and Summit Therapeutics (SMMT) at 23.13 prices even higher, above its industry range.

Valuation Metrics